S-Equol in Alzheimer's Disease (SEAD) Trial

Plain-language summary

This study evaluates S-Equol compared with a placebo in people with very mild to mild Alzheimer's disease. Patients with very mild (CDR 0.5) or mild (CDR 1) Alzheimer's disease who have a study partner were able to take part. The study was carried out in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Russell Swerdlow, MD

Intervention

S -Equol, Placebo

Start date

7/1/2014

Estimated completion

4/1/2016

Countries

United States

Related genes

Locations

• Kansas City, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Very mild (CDR 0.5) or mild (CDR 1) AD at time of last KU ADC assessment
* Have a study partner
* Speak English as primary language

Exclusion Criteria:

* No viable study partner
* Report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
* Use any type of estrogen replacement therapy